ArticlePregnancy (Hoboken, N.J.)2026
Cost-effectiveness of implementing a multidisciplinary team approach in the management of placenta accreta spectrum.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Placenta accreta spectrum (PAS) is associated with high maternal morbidity. Recent studies have shown that a multidisciplinary team (MDT) approach to managing PAS can improve outcomes. This study aimed to evaluate the cost-effectiveness of implementing an MDT for the management of PAS. Methods: A decision-analytic model was built using TreeAge software to compare the outcomes and cost-effectiveness of the MDT approach versus the standard of care. The theoretical cohort included 5000 individuals in the United States with PAS annually. Maternal outcomes included severe postpartum hemorrhage (>2000 mL estimated blood loss), adjacent organ injury, intensive care unit (ICU) admission, maternal death, and hospital readmission. The cost of the MDT was estimated by assuming that there would be specific maternal-fetal medicine (MFM) physician and nursing leadership assigned for administrative coordination and estimates of the cost of the multidisciplinary clinicians during the PAS cases. Model inputs were derived from the literature. The cost-effectiveness threshold was $100,000/quality-adjusted life-year (QALY). Sensitivity analyses were performed to assess the robustness of the results. Results: An MDT approach for the management of PAS resulted in 3724 fewer severe postpartum hemorrhages, 139 fewer adjacent organ injuries, 506 fewer ICU admissions, 87 fewer hospital readmissions within 6 months, and one less maternal death compared to standard of care. When assuming a minimum baseline of 15 PAS cases per year, the MDT approach was a dominant strategy resulting in a $12.1 million cost reduction and an increase of 26 QALYs relative to standard care. One-way sensitivity analyses on the cost of the MDT per PAS case and the number of PAS cases per medical center demonstrated that the MDT strategy remains cost effective when the cost per case was less than $9290 and when centers treat at least seven PAS cases annually. Conclusion: Implementing an MDT was cost effective and improved maternal outcomes. These findings may inform interventions that promote MDT in the management of this high-risk condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.